|
|
BiomedReports: News and FDA Updates for Tianyin (NYSE:TPI), Vyteris (OTC:VYTR), YM BioSciences (NYSE:YM)
|
BiomedReports: News and FDA Updates for Synta (NASDAQ:SNTA), Teva (NASDAQ:TEVA), Active Biotech (NASDAQ:ACTI)
|
BiomedReports: News and FDA Updates for PPD (Nasdaq:PPDI), Repros Therapeutics (Nasdaq:RPRX), Stem Cell Therap
|
India Suspends Launching Of Genetically-modified Vegetable Crop On Safety Concerns
|
Fujifilm Makes a Full-scale Entry into Clinical Development and Pharmaceutical Marketing
|
Sunesis Licenses Drug Discovery Technology To Private Company - Stocks To Watch
|
How one bull is playing Gilead
|
BiomedReports: News and FDA Updates for Talecris (Nasdaq:TLCR), Teva (Nasdaq:TEVA)
|
BiomedReports: News and FDA Updates for EpiCept (Nasdaq:EPCT), Health Discovery (OTC:HDVY), Human Genome Scien
|
FDA: Frequent Tysabri Use Raises PML Risk
|
Different folks, different strokes
|
BiomedReports: News and FDA Updates for GTC (NASDAQ:GTCB), Health Discovery (OTC:HDVY), Vermillion (OTC:VRML),
|
BiomedReports: News and FDA Updates for BioClinica (NASDAQ:BIOC), Catalyst Health (NASDAQ:CHSI), CEL-SCI (NYSE
|
BiomedReports: News and FDA Updates for EpiCept (Nasdaq:EPCT), ERT (Nasdaq:ERES), Genzyme (NASDAQ:GENZ)
|
PROLOR Biotech Says Growth Harmone Seems More Potent Than Current Commercial Versions - Stocks To Watch (Updat
|
PROLOR Biotech Says Longer-acting Growth Harmone Meets Primary Goals In Early Trials - Stocks To Watch
|
27 Jan 2010 - HORIBA Medical launches Pentra C200 compact chemistry analyser
|
Anthera Pharmaceuticals Estimates Pricing IPO In $13-$15 Per Share Range
|
Novo Nordisk Q4 net profit decreases
|
BiomedReports: News and FDA Updates for Teva (Nasdaq:TEVA), Trimeris (Nasdaq:TRMS), U.S. Physical Therapy (NAS
|
